Stiefel, a GlaxoSmithKline company, announced that Sorilux (calcipotriene) Foam, 0.005%, is now available for the topical treatment of plaque psoriasis in patients aged ≥18 years.

Two placebo controlled clinical trials were conducted comparing Sorilux Foam to vehicle in the treatment of patients with mild to moderate plaque psoriasis. In the studies, efficacy evaluation was carried out at Week Eight, with treatment success being defined as a score of “clear” (Grade 0) to “almost clear” (Grade 1) and at least a two grade improvement from the baseline score. In one study, 27% of patients treated with Sorilux Foam experienced treatment success vs. 16% using vehicle alone. In another study, 14% of patients treated with Sorilux Foam were classified as successful vs. 7% percent of patients treated with vehicle only. In this study patients graded as “mild” at baseline showed a greater response to vehicle than to Sorilux Foam.

Sorilux Foam was found to be effective in treating mild to moderate plaque psoriasis. It contains the vitamin D3 analog calcipotriene, a synthetic compound similar to natural vitamin D3; however, the exact mechanism of action contributing to the clinical efficacy in the treatment of psoriasis is unknown. Based on consistent and good-quality patient-oriented evidence, vitamin D3 analogs are a recommended treatment for psoriasis according to the American Academy of Dermatology’s guidelines. Sorilux Foam is formulated with the proprietary delivery technology, VersaFoam.

Sorilux Foam is supplied in 60g and 120g aluminum cans.

For more information call (888) 784-3335 or visit